Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

University of Chicago, Chicago, Il, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chicago, Il
Treatments:Biologic therapyHospital:University of Chicago
Drugs:Journal:Link
Date:Apr 2014

Description:

Patients:
This phase 2 study involved 50 advanced or metastatic urothelial cancer patients who had received previous chemotherapy. The median patient age was 68.5 years and 80% were male.

Treatment:
Patients were treated with the biological therapy agent called volasertib, which is an inhibitor of the PIK protein that interferes with cancer cell growth.

Toxicities:
There were 3 reported deaths due to disease progression. Grade 3-4 anemia, thrombocytopenia, and neutropenia were also reported.

Results:
The median overall survival was 8.5 months.

Support:
This study was partially supported by Boehringer Ingelheim.

Correspondence: Dr. Walter M. Stadler; email: [email protected]



Back